STTR Phase I: Scaleable, Inexpensive Production of siRNA in E. coli

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 0738336
Agency Tracking Number: 0738336
Amount: $150,000.00
Phase: Phase I
Program: STTR
Awards Year: 2008
Solicitation Year: N/A
Solicitation Topic Code: BT
Solicitation Number: NSF 07-551
Small Business Information
BioTex, Inc.
8058 El Rio St., Houston, TX, 77054
DUNS: 969792050
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 George Jackson
 DPhil
 (713) 741-0111
 bill@biotexmedical.com
Business Contact
 George Jackson
Title: DPhil
Phone: (713) 741-0111
Email: bill@biotexmedical.com
Research Institution
 University of Houston
 George Fox
 316 E Cullen
Houston, TX, 77204 2015
 (713) 743-9104
 Nonprofit college or university
Abstract
This Small Business Technology Transfer Phase I project develops molecular biology, biochemical engineering, and purification techniques to provide small interfering RNA or siRNA molecules on at large-scale and at low cost compared to available techniques. In recent years, siRNA's have been recognized as potent gene-silencing agents via RNA interference (RNAi). Genes for important diseases such as cancer, HIV, and hepatitis have already been shown to be controllable by siRNA action. Applications of siRNA's now warrant large-scale manufacture of siRNAs for the purposes of RNAi associated studies and as pharmaceutical agents. Unique to the technology is our well demonstrated evidence that RNA insert sequences can be harbored in larger ribosomal RNA (rRNA) carriers and produced at high levels within E. coli by conventional fermentation. Following fermentation, the desired siRNA is excised and purified for large-scale production of the RNA product. The broader impacts of this research is to provide a general, large-scale production tool applicable to a wide range of future novel RNA products. In addition to siRNA production, the methods proposed here can be used for large-scale production of micro-RNAs, aptamers, antisense therapeutics, or other short RNA molecules that are also of considerable interest for structural and pharmacological applications. The associated products and RNA expression systems are expected to have considerable commercial value, first in the research community and eventually as pharmaceuticals. This project will also result in fundamental scientific knowledge regarding RNA structure, enzymatic action, and purification of particular RNA molecules.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government